Veloxis Pharmaceuticals AS:企業の戦略的SWOT分析

◆英語タイトル:Veloxis Pharmaceuticals AS - Strategic SWOT Analysis Review
◆商品コード:GDPH61177SA
◆発行会社(調査会社):GlobalData
◆発行日:2020年12月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Veloxis Pharmaceuticals AS – Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Veloxis Pharmaceuticals A/S (Veloxis), a subsidiary of Asahi Kasei Corp, is a specialty pharmaceutical company that identifies, develops and commercializes pharmaceutical drugs in transplantation and adjacent therapies. The company lead product is ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients. ENVARSUS is developed based on the company’s proprietary, patented drug delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company sells ENVARSUS XR to government agencies, specialty pharmacies, managed healthcare organizations, wholesalers and retail customers across the US, Europe and worldwide. Veloxis is headquartered in Copenhagen, Denmark.

Veloxis Pharmaceuticals AS Key Recent Developments

Jan 29,2020: Nasdaq Copenhagen has accepted Veloxis Pharmaceuticals request for Delisting of its Shares from Nasdaq Copenhagen
Nov 26,2019: Asahi Kasei offers to buy Veloxis Pharmaceuticals for $1.3bn
Nov 12,2019: Veloxis Pharmaceuticals announces financial results for the first nine months of 2019
Aug 08,2019: Veloxis Pharmaceuticals announces financial results for the first six months of 2019
Jul 22,2019: Veloxis revises outlook for 2019 based on strong performance

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Veloxis Pharmaceuticals AS – Key Facts
Veloxis Pharmaceuticals AS – Key Employees
Veloxis Pharmaceuticals AS – Key Employee Biographies
Veloxis Pharmaceuticals AS – Major Products and Services
Veloxis Pharmaceuticals AS – History
Veloxis Pharmaceuticals AS – Company Statement
Veloxis Pharmaceuticals AS – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Veloxis Pharmaceuticals AS – Business Description
Veloxis Pharmaceuticals AS – SWOT Analysis
SWOT Analysis – Overview
Veloxis Pharmaceuticals AS – Strengths
Veloxis Pharmaceuticals AS – Weaknesses
Veloxis Pharmaceuticals AS – Opportunities
Veloxis Pharmaceuticals AS – Threats
Veloxis Pharmaceuticals AS – Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Veloxis Pharmaceuticals AS, Recent Deals Summary
Section 4 – Company’s Recent Developments
Jan 29, 2020: Nasdaq Copenhagen has accepted Veloxis Pharmaceuticals request for Delisting of its Shares from Nasdaq Copenhagen
Nov 26, 2019: Asahi Kasei offers to buy Veloxis Pharmaceuticals for $1.3bn
Nov 12, 2019: Veloxis Pharmaceuticals announces financial results for the first nine months of 2019
Aug 08, 2019: Veloxis Pharmaceuticals announces financial results for the first six months of 2019
Jul 22, 2019: Veloxis revises outlook for 2019 based on strong performance
May 06, 2019: Veloxis Pharmaceuticals announces financial results for the first three months of 2019
Feb 27, 2019: Veloxis Pharmaceuticals releases annual report for 2018
Jan 03, 2019: Mark Hensley promoted to Chief Commercial Officer of Veloxis Pharmaceuticals
Section 5 – Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

List of Tables
Veloxis Pharmaceuticals AS, Key Facts
Veloxis Pharmaceuticals AS, Key Employees
Veloxis Pharmaceuticals AS, Key Employee Biographies
Veloxis Pharmaceuticals AS, Major Products and Services
Veloxis Pharmaceuticals AS, History
Veloxis Pharmaceuticals AS, Subsidiaries
Veloxis Pharmaceuticals AS, Key Competitors
Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Veloxis Pharmaceuticals AS, Recent Deals Summary

★海外企業調査レポート[Veloxis Pharmaceuticals AS:企業の戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Business Connexion Group Limited:企業の戦略的SWOT分析
    Business Connexion Group Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • NorthWestern Corporation (NWE)-石油・ガス分野:企業M&A・提携分析
    Summary NorthWestern Corporation, doing business as NorthWestern Energy, is an integrated electric utility which generates, transmits, and distributes electricity and distributes natural gas in South Dakota, Nebraska and Montana. It produces energy from wind, hydro, natural gas, and coal-fired sourc …
  • Marksans Pharma Ltd (MARKSANS):製薬・医療:M&Aディール及び事業提携情報
    Summary Marksans Pharma Ltd (Marksans Pharma) is a pharmaceutical company that develops, manufactures and markets branded formulations and generic products. The company manufactures non-sterile liquids, ointments and powder products. It offers solid oral dosage in form of tablets, hard gelatin capsu …
  • Recipharm AB:企業のM&A・事業提携・投資動向
    Recipharm AB - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Recipharm AB Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • AMETEK Inc (AME)-医療機器分野:企業M&A・提携分析
    Summary AMETEK Inc (AMETEK) is an electronic products manufacturing company that manufactures electronic instruments and electromechanical devices. The company's products include medical materials, motion control systems, sub assemblies and connectors, electrical cord reels, gauges, titanium alloys …
  • Aqua Bio Technology ASA (ABT):企業の財務・戦略的SWOT分析
    Summary Aqua Bio Technology ASA (ABT) is a biotechnology company that develops, produces and markets new active ingredients. The company’s products comprise Aquabeautine XL and Smids. Its product Aquabeautine XL is derived from the hatching fluid of salmon. ABT’s products are based on research and d …
  • Nice-Pak Products, Inc.:企業の戦略・SWOT・財務情報
    Nice-Pak Products, Inc. - Strategy, SWOT and Corporate Finance Report Summary Nice-Pak Products, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Samyang Comtech Co., Ltd.:企業の戦略・SWOT・財務情報
    Samyang Comtech Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Samyang Comtech Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Vattenfall AB:企業の戦略的SWOT分析
    Vattenfall AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Danubius Hotel And Spa Private Company Limited
    Danubius Hotel And Spa Private Company Limited - Strategy, SWOT and Corporate Finance Report Summary Danubius Hotel And Spa Private Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • Valecha Engineering Ltd:企業の戦略・SWOT・財務分析
    Valecha Engineering Ltd - Strategy, SWOT and Corporate Finance Report Summary Valecha Engineering Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Fagron NV (FAGR):企業の財務・戦略的SWOT分析
    Summary Fagron NV (Fagron), is a pharmaceutical company that provides compounding solutions. The company offers products such as raw materials, flammable products, extracts and tinctures; anesthetic, syrups, ointment bases, medispend, triturations, suspension media, phyto pharmaflore, capsicards sys …
  • Tufts University-製薬・医療分野:企業M&A・提携分析
    Summary Tufts University (Tufts) is an educational and research university that offers undergraduate and postgraduate courses in various fields. The university offer courses in anthropology, applied mathematics, architectural engineering, physics, archaeology, Asian American studies, biochemistry, b …
  • Centrica Plc (CNA):石油・ガス:M&Aディール及び事業提携情報
    Summary Centrica Plc (Centrica) is an integrated energy company. It carries out electricity generation through and combined cycle gas turbine (CCGT) power stations, and nuclear power plants through its stake in EDF Energy Nuclear Generation. Centrica secures and supply gas and electricity to homes a …
  • Royal IHC:石油・ガス:M&Aディール及び事業提携情報
    Summary Royal IHC (IHC), formerly IHC Merwede BV is a shipbuilding company that offers engineering solutions. The company’s product portfolio includes dredging equipment, motion control and automation equipment, decommissioning equipment, offshore foundation equipment and metal construction kits. IH …
  • Sensus BV:企業の戦略・SWOT・財務情報
    Sensus BV - Strategy, SWOT and Corporate Finance Report Summary Sensus BV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Randox Laboratories Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Randox Laboratories Ltd (Randox) is a clinical diagnostic company that manufactures and provides clinical diagnostic solutions to laboratories. The company’s products include biochip analyzers, biochip immunoassays, clinical chemistry analyzers and diagnostic reagents among others. It offers …
  • Oncology Venture ApS-製薬・医療分野:企業M&A・提携分析
    Summary Oncology Venture ApS (Oncology Venture), a subsidiary of Oncology Venture Sweden AB is a drug development company that discovers new oncology products, and rescuing failed ones. The company provides gene-tumor-technology for identifying patients with resistance to anticancer drug. Its activi …
  • Total Petrochemicals & Refining USA Inc:企業の戦略的SWOT分析
    Total Petrochemicals & Refining USA Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • BioLineRx Ltd (BLRX):製薬・医療:M&Aディール及び事業提携情報
    Summary BioLineRx Ltd (BioLineRx) is a clinical stage biopharmaceutical company that focuses on the identification, in-licensing, and development of products to address unmet medical needs. The company focuses mainly on cancer and immunology. Its’s product pipeline includes BL-8040, a short peptide …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆